386 related articles for article (PubMed ID: 28867130)
1. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
3. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
[TBL] [Abstract][Full Text] [Related]
5. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
[TBL] [Abstract][Full Text] [Related]
6. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
7. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study.
Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M
Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223
[TBL] [Abstract][Full Text] [Related]
8. Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity.
Vogel RN; Strampe M; Fagbemi OE; Visotcky A; Tarima S; Carroll J; Costakos DM
Ophthalmology; 2018 Mar; 125(3):444-452. PubMed ID: 29103792
[TBL] [Abstract][Full Text] [Related]
9. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
13. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
14. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
15. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
16. Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.
Lepore D; Ji MH; Quinn GE; Amorelli GM; Orazi L; Ricci D; Mercuri E
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):180-186. PubMed ID: 32211908
[TBL] [Abstract][Full Text] [Related]
17. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
18. PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY.
Garcia Gonzalez JM; Snyder L; Blair M; Rohr A; Shapiro M; Greenwald M
Retina; 2018 Apr; 38(4):764-772. PubMed ID: 28267112
[TBL] [Abstract][Full Text] [Related]
19. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
[TBL] [Abstract][Full Text] [Related]
20. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
